Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

March 21, 2011 15:27 ET

Theralase Appoints General Manager for Its Therapeutic Division

Córdoba to manage sales, marketing, production, clinical services and regulatory affairs departments

TORONTO, ONTARIO--(Marketwire - March 21, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that effective immediately, Mr. Jorge Cordoba has been appointed as General Manager - Therapeutic Division for Theralase's line of proprietary therapeutic medical laser products. Mr. Cordoba, reporting to Roger Dumoulin-White, President and CEO, will have general management responsibilities over the sales, marketing, production, clinical services and regulatory affairs departments.

Mr. Cordoba has over 16 years of experience in leading numerous high technology manufacturing companies to success, providing general management expertise in local and international sales, marketing, production, operations and regulatory affairs. His last position, prior to joining Theralase, was as Director Of Operations for a $17 million aerospace organization turnaround situation, in which Mr. Cordoba, through a number of different initiatives, achieved an increase in productivity of over 400% in less than 2 years. Prior to that, Mr. Cordoba, in the capacity of a Project Operations Manager, successfully launched a 250,000 square foot, $40 million facility for manufacturing high precision assemblies for a division of Magna Inc. In an earlier position, he was the sales and marketing manager for a high tech equipment manufacturer, responsible for sales in excess of $10 million annually.

"I am excited to be part of such a world-class medical organization as Theralase. Under the direction of Roger Dumoulin-White, Theralase has systematically developed valuable intellectual property in the medical laser space and in my estimation is now positioned to rapidly execute on its growth strategy," said Jorge Cordoba. "I accepted the position because Theralase has such wonderful upside, attracting a dedicated team of professionals able to take this intellectual property to the next level and dramatically increase its revenue over the next few years. I look forward to following in Roger's footsteps to dramatically grow the therapeutic division of the Company."

Mr. Cordoba obtained a Master's of Business from the Ivey School of Business, University of Western Ontario, London, Ontario in 2005, a Master's of Science in Advanced Manufacturing Technology from the University of Manchester, Manchester, England in 1993 and a Bachelor of Mechanical-Electrical Engineering from the National University, Mexico City, Mexico in 1989.

"It is a pleasure to have someone with Jorge's background and experience join Theralase to grow the therapeutic laser division in Canada, the United States and internationally," said Roger Dumoulin- White, President & CEO of Theralase Technologies Inc. "I look forward to focusing on commercializing the patented Photo Dynamic Compounds (PDCs) for cancer destruction and bacterial sterilization applications, as I transfer my knowledge on the therapeutic medical laser technology to Jorge, so he can adopt my vision for Theralase and put his own mark on it in 2011 and beyond."

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information